425: Alumis and ACELYRIN Announce Merger to Create Immunology Powerhouse

Alumis and ACELYRIN are merging in an all-stock transaction to create a combined company with a diversified late-stage immunology pipeline and stronger financial resources.

Summary

• Alumis and ACELYRIN have announced a merger agreement where ACELYRIN stockholders will receive 0.4274 shares of Alumis stock for each ACELYRIN share.
• This results in a pro forma ownership of approximately 55% for Alumis stockholders and 45% for ACELYRIN stockholders.
• The combined company will operate under the Alumis name, with headquarters remaining in South San Francisco, and will welcome two additional directors from ACELYRIN's board.
• The merger is expected to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
• The merger aims to create a company with a diversified late-stage portfolio, including Alumis' TYK2 inhibitors (ESK-001 and A-005) and ACELYRIN's lonigutamab.
• Alumis' lead program, ESK-001, is in Phase 3 trials for psoriasis with topline data expected in the first half of 2026, and Phase 2b trials for lupus with topline data also expected in 2026.
• A-005, a brain-penetrant TYK2 inhibitor, is planned to enter Phase 2 trials for multiple sclerosis in the second half of the year.
• Alumis plans to re-evaluate the development plan for lonigutamab, an anti-IGF-1R for thyroid eye disease, to determine the most capital-efficient path forward.
• The combined company's pro forma cash position is $737 million as of the end of 2024, providing cash runway into 2027.
• Alumis leadership will remain in place, emphasizing a disciplined capital approach to maximize returns.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the merger, highlighting the potential for a stronger, more diversified company with a solid financial foundation. While there are inherent risks in any merger, the overall tone is optimistic about the future prospects of the combined entity.

Positives

• The merger creates a company with a diversified late-stage pipeline in immunology.
• The combined company has a stronger financial position with a cash runway into 2027.
• Alumis' leadership team will remain in place, providing continuity.
• The merger is expected to enhance value for shareholders through increased resources and combined expertise.
• Alumis has a disciplined capital approach, which is expected to continue post-merger.
• The merger allows for a re-evaluation of lonigutamab's development plan to optimize capital efficiency.

Negatives

• There is uncertainty regarding the future development path for lonigutamab.
• The merger is subject to stockholder approval and customary closing conditions, which could delay or prevent the transaction.
• Integration risks exist in combining the two companies' operations and personnel.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals for the transaction may not be received.
• The announcement of the transaction may affect Alumis' or ACELYRIN's ability to retain key personnel and maintain relationships.
• The transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the transaction could result in expense or delay.
• The anticipated benefits and synergies of the transaction may not be fully realized.
• There are risks relating to the value of Alumis securities to be issued in the proposed transaction.
• Potential delays in initiating, enrolling or completing preclinical studies and clinical trials.

Future Outlook

The combined company anticipates a strong financial position to carry them forward beyond immediate readouts and prepare for potential commercialization of ESK-001. They plan to execute against key milestones and evaluate the most capital-efficient path for lonigutamab.

Management Comments

• Martin Babler: 'What particularly is compelling about this transaction, and we'll speak more about this in a moment, is that it creates a highly differentiated late-stage portfolio that were well-positioned to advance through multiple upcoming milestones, with significant combined financial strength.'
• Mina Kim: 'We're pleased with the terms, both the value achieved for ACELYRIN stockholders and the development synergies for lonigutamab.'
• John Schroer: 'We are excited about the value creation opportunities that lie ahead for all of our stakeholders and both companies stockholders.'

Industry Context

This merger reflects a trend in the biotech industry towards consolidation to create companies with diversified pipelines and stronger financial positions, particularly in the competitive immunology space. The deal aims to create a more resilient entity capable of navigating the challenges of drug development and commercialization.

Comparison to Industry Standards

• The decision to re-evaluate the Phase 3 program for lonigutamab is notable, given the success of Horizon Therapeutics' TEPEZZA in the thyroid eye disease market.
• TEPEZZA achieved significant sales, but the market may have unmet needs that lonigutamab could address with a differentiated safety profile and subcutaneous administration.
• Alumis' TYK2 inhibitors compete with Bristol Myers Squibb's SOTYKTU, but Alumis believes its drug will show a dose response where SOTYKTU did not due to differences in PK and tolerability.
• The combined company's cash runway into 2027 positions it favorably compared to other biotech companies that may need to raise additional capital in the near term.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN will be impacted by the merger, with ACELYRIN shareholders receiving Alumis stock.
• Employees of both companies may experience changes as a result of the integration.
• Patients may benefit from the combined company's ability to advance promising therapies.
• The merger may impact relationships with partners, suppliers, and other stakeholders.

Next Steps

• Alumis and ACELYRIN will seek stockholder approval for the merger.
• Alumis will file a registration statement on Form S-4 with the SEC.
• The companies will work to satisfy customary closing conditions.
• Alumis will re-evaluate the development plan for lonigutamab.
• Alumis will continue to advance its TYK2 inhibitor programs.
• The combined company will integrate operations and personnel post-closing.

Key Dates